Close Menu

NEW YORK – Investment bank Oppenheimer on Wednesday initiated coverage on diagnostics company Bionano Genomics with a rating of Outperform and a price target of $1.50.

In a note to investors, analyst Kevin DeGeeter said the company is transitioning from selling optical mapping equipment to research labs to selling clinical diagnostics that have the potential to replace microarrays for cytogenetics analysis.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.

Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.

Science reports that a Dutch research funding agency is combating a ransomware attack.

In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.